Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Sep 11, 2019--
LOS ANGELES--(BUSINESS WIRE)--Sep 11, 2019--